Research Archives | Mr Rahim Kaba

A recent analysis from the CLEAR trial (NCT04338776), shared in Urology Times, has highlighted that UroLift therapy may provide men with Benign Prostate Enlargement a faster recovery in the early period following treatment compared to Rezūm therapy, while both treatments showed similar improvements in urinary symptoms over time.

The CLEAR trial findings

The CLEAR trial followed 184 men with Benign Prostate Enlargement, assessing symptom scores, recovery timelines, and quality of life. At one month, patients treated with UroLift demonstrated greater improvements in symptom scores and quality of life, as well as a quicker return to normal activities. However, by three and twelve months post-treatment, outcomes between UroLift and Rezūm were comparable, with both therapies significantly improving urinary symptoms while preserving sexual function for most men.

These findings offer reassurance to men considering minimally invasive treatments, confirming that both UroLift and Rezūm are effective while offering slightly different recovery experiences. The trial continues to assess the longer term outcomes of these treatments (expected Dec 2025).

UroLift Therapy

UroLift is a minimally invasive procedure for men with Benign Prostate Enlargement that uses small, permanent implants to hold back the enlarged prostate tissue that is blocking the urethra. This treatment restores normal urine flow without the need for cutting, heating, or removing prostate tissue, allowing for a rapid return to daily activities and preserving sexual function, including ejaculation and erectile function. It is typically performed under local or light general anaesthesia and is often completed as a day-case procedure, with many men noticing symptom improvement soon after treatment.

Rezūm Therapy

Rezūm therapy also offers a minimally invasive solution for Benign Prostate Enlargement but uses water vapour (steam) to treat excess prostate tissue. The steam is delivered directly into the prostate, causing the treated cells to shrink and be reabsorbed by the body over several weeks, relieving the obstruction. Rezūm can be performed under local anaesthetic with sedation, with many men experiencing a gradual but significant improvement in urinary symptoms while preserving sexual function.

Urolift vs Rezūm

Both UroLift and Rezūm are designed to relieve urinary symptoms in men with Benign Prostate Enlargement while avoiding the risks of traditional surgery and preserving sexual function. UroLift often provides a faster initial recovery, with quicker symptom relief and minimal downtime. Rezūm offers a different approach, using thermal therapy to gradually reduce prostate size, and may be suitable for men who prefer a treatment without implants.

Mr Rahim Kaba offers a comprehensive range of advanced treatment options for men with Benign Prostate Enlargement, including UroLift and Rezūm therapies. During your consultation, Mr Kaba will carry out a detailed assessment of your symptoms, prostate size, and personal treatment goals to determine which treatment is most suitable. You will receive clear, personalised advice to guide your treatment journey.

If you are experiencing urinary symptoms and would like to discuss treatment options, please get in touch to arrange a consultation. Call us on +441926 436316 or email us at laura.quince@nuffieldhealth.com.

Prostate cancer in the UK

Prostate cancer is the most common cancer in men in the UK, affecting approximately 1 in 8 men during their lifetime. However, most early-stage cancers are slow-growing and may not require immediate treatment. That’s why the current pathway prioritises mpMRI before biopsy, effectively identifying clinically significant cancers while avoiding unnecessary intervention.

Prostate Cancer UK and a UK clinical consensus peer-review found that while routine screening of asymptomatic men isn’t recommended, primary-care professionals should proactively discuss PSA testing with higher‑risk men – including those of Black ethnicity, with a strong family history, or known genetic risks – and ensure informed decision-making.

Elevated PSA investigations

Consultant Urological Surgeon Mr Rahim Kaba follows a patient-centred approach when managing those with elevated PSA levels. His protocol encompasses:

A detailed discussion of PSA velocity and density to interpret individual risk

Routine use of multi-parametric MRI (mpMRI) of the prostate before any biopsy is considered – a method shown to improve diagnostic accuracy and reduce unnecessary biopsies

When imaging suggests concern, performing targeted and systematic transperineal biopsy

Mr Kaba explains: “Before deciding whether to have a PSA test, you should discuss it taking into account your personal preferences and risk factors,” stressing that the decision is never taken lightly.

Key recommendations

The updated guidance reinforces that PSA testing should be offered on an individual basis, especially in men at higher risk. Therefore, men over 50, or over 45 who are of African descent, have a family history of prostate cancer, or carry genetic risk factors, should discuss PSA testing with their Consultant.

Mr Rahim Kaba’s practice, with its emphasis on mpMRI and precision transperineal biopsy, exemplifies a modern, evidence-based approach that aligns with current UK recommendations. This pathway helps ensure that prostate cancer is detected accurately, interventions are appropriate, and men can make well-informed decisions about their health.

Contact Mr Kaba’s secretary to book a consultation: call us on +441926 436316 or email us at laura.quince@nuffieldhealth.com.

Study shows UroLift may offer faster early recovery than Rezūm

The CLEAR trial findings

UroLift Therapy

Rezūm Therapy

Urolift vs Rezūm

New guidance for PSA testing and cancer detection

Prostate cancer in the UK

Elevated PSA investigations

Key recommendations

Member of:

Insured by:

Contact

Clinic